Viagra to go on sale in UK without prescription

19 February 2007

As part of a pilot scheme to be launched on February 14, 2007, three retail pharmacies in Manchester, UK, will offer world drug giant Pfizer's erectile dysfunction drug Viagra (sildenafil citrate) without a prescription.

The Boots Pharmacy ED Programme costs L50 ($97) for the initial screening and supply of four tablets, L37.50 for subsequent private doctor consultation and then from L21.25 for four tablets further supply. National roll out of the program will be assessed later in the year.

The scheme is open to men aged betweem 30 and 65 who are suffering from ED and involves a consultation in a private area with a pharmacist who has been trained to follow a strict protocol to assess suitability for this specific medicine. The pharmacist will take a medical history and establish symptoms of ED as well as checking blood pressure, cholesterol and blood glucose levels. The consultation also takes into account any other medications or medical conditions the patient may have that would affect their suitability.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight